* Trial objective: To test the hypothesis that remote per-postconditioning in connection with primary PCI will reduce myocardial infarct size patients with STEMI. * Trial Design: Placebo controlled randomized study with parallel groups * Primary Endpoint: Myocardial infarct size expressed as a percentage of the myocardium at risk determined by Cardiac Magnetic Resonance (CMR) day 4-7 * Efficacy Parameters: Myocardial infarct size expressed as a percentage to the myocardium at risk determined by CMR at 6 months. * Global left ventricular function determined by left ventricular ejection fraction determined by CMR. * Microvascular obstruction determined by CMR day 4-7. Quantified ECV (extracellular volume) in left ventricular as myocardium at risk day 4-7 and remodelling parameters day 180. * Safety Parameters: Major adverse cardiovascular events.
See above. 3 patients left to include.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Primary Percutanous Coronary Intervention is performed in both Groups.
Karolinska University Hospital
Stockholm, Sweden
Danderyds Hospital
Stockholm, Sweden
Södersjukhuset
Stockholm, Sweden
Myocardial infarct size expressed as a percentage of the myocardium at risk determined by Cardiac Magnetic Resonance
Time frame: 4-7 days following index event
Myocardial infarct size expressed as a percentage to the myocardium at risk determined by Cardiac Magnetic Resonance
Time frame: 6 months following index event
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.